Results 61 to 70 of about 5,215,493 (360)

Function‐driven design of a surrogate interleukin‐2 receptor ligand

FEBS Letters, EarlyView.
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang   +9 more
wiley   +1 more source

The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer

Cancer Immunology, Immunotherapy
Background Local recurrence after surgical resection is a major clinical challenge in patients with advanced head and neck cancer (HNC). We previously reported using transfer of a flap treated with dendritic cells (DCs) (“immuno-flap”) as a novel cancer ...
Hiroaki Mori, Yasuto Akiyama, Chie Maeda, Akari Kanematsu, Tadashi Ashizawa, Kazue Yamashita, Haruo Miyata, Akira Iizuka, Tomoatsu Ikeya, Yoshichika Yasunaga, Jun Araki   +10 more
doaj   +1 more source

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

Journal of Hematology & Oncology
Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds.
Qiang Lu, Dongquan Kou, Shenghan Lou, M. Ashrafizadeh, A. Aref, Israel Cañadas, Yu Tian, Xiaojia Niu, Yuzhuo Wang, Pedram Torabian, Lingzhi Wang, Gautam Sethi, Vinay Tergaonkar, Franklin Tay, Zhennan Yuan, Peng Han   +15 more
semanticscholar   +1 more source

Exosomes as smart drug delivery vehicles for cancer immunotherapy

Frontiers in Immunology, 2023
Exosomes (Exos) as drug delivery vehicles have been widely used for cancer immunotherapy owing to their good biocompatibility, low toxicity, and low immunogenicity. Some Exos-based cancer immunotherapy strategies such as tuning of immunosuppressive tumor
Huan Zhang, Simiao Wang, Man Sun, Yaxin Cui, Jianmin Xing, Lesheng Teng, Zhifang Xi, Zhaogang Yang   +7 more
semanticscholar   +1 more source

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy [PDF]

, 2018
Breast cancer patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and relapse ...
Manjili, Masoud H.
core   +1 more source

Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions

FEBS Letters, EarlyView.
Mutant p53 gain‐of‐function is thought to be mediated by interaction with other transcription factors. We identify multiple ETS transcription factors that can bind mutant p53 and found that this interaction can be promoted by a PXXPP motif. ETS proteins that strongly bound mutant p53 were upregulated in ovarian cancer compared to ETS proteins that ...
Stephanie A. Metcalf, Nicholas F. Downing, Kaitlyn M. Mills, Samuel C. Metcalfe, Alexander E. Kritzer, Lindsey D. Mayo, Peter C. Hollenhorst   +6 more
wiley   +1 more source

Peripheral Blood CD8+ T-Lymphocyte Subsets Are Associated with Prognosis in Prostate Cancer Patients

Onco, 2023
Background: Various studies have reported associations between frequencies of total peripheral blood lymphocytes and prostate cancer prognosis, but none so far has addressed the prognostic role of CD8+ T-lymphocyte subsets.
Constantin N. Baxevanis, Savvas Stokidis, Maria Goulielmaki, Angelos D. Gritzapis, Sotirios P. Fortis   +4 more
doaj   +1 more source

New perspectives in cancer immunotherapy: targeting IL-6 cytokine family

Journal for ImmunoTherapy of Cancer, 2023
Chronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor ...
Maria Florencia Soler, A. Abaurrea, P. Azcoaga, A. Araujo, M. Caffarel   +4 more
semanticscholar   +1 more source

Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. [PDF]

, 2019
Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming.
Canter, Robert J, Gingrich, Alicia A, Modiano, Jaime F   +2 more
core   +2 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source